Novo Nordisk Abruptly Ends Partnership with Hims, Claiming ‘Sham Compounding’ GLP-1 Drugs
Bad blood is brewing among some major players in the weight loss world. Novo Nordisk, the creator of Ozempic and Wegovy, cut short its partnership with telehealth company Hims & Hers Health Inc. over allegations that the latter is still trying to mass-market cheaper versions of the GLP-1 drugs. Bloomberg News reported the abrupt dissolution of the partnership Monday, just two months after it was struck. Novo claims that Hims is using “deceptive marketing” to widely sell compounded semaglutide t